Novavax, Inc. (NASDAQ:NVAX) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET

Company Participants

Erika Schultz - Senior Director of IR

John Jacob - President & Chief Executive Officer

Filip Dubovsky - Chief Medical Officer

John Trizzino - Chief Commercial Officer & Chief Business Officer

James Kelly - Chief Financial Officer & Treasurer

Conference Call Participants

Roger Song - Jefferies

Eric Joseph - JPMorgan

Mayank Mamtani - B. Riley

Operator

Good morning, and welcome to Novavax First Quarter 2023 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Erika Schultz, Senior Director, Investor Relations. Please go ahead.

Erika Schultz

Good afternoon, and thank you all for joining us today to discuss our first quarter 2023 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.

Please turn to slid 2. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including information relating to the future of Novavax, its key strategic priorities, operating plans, objective and prospects. Its future financial or business performance, conditions or strategies, including projections on revenue and reductions in expenses, and as global restructuring and cost reduction initiative, key commercial goals, including transitioning to our traditional commercial model, future product demand trends, the ongoing development of our vaccine candidates, including advancing multiple variants strain, strain selection, anticipating timing of trials and results, the scope, timing and outcome of future regulatory filings and actions, the efficacy, safety and intended utilization of our vaccine candidates, including against COVID variants, the global market opportunities for our vaccine candidates, our manufacturing capacity, and the future availability of our vaccine candidates and key upcoming milestones.

Each forward looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding those factors appears under the heading cautionary note regarding forward looking statements in the slide deck we issued this afternoon, and under the heading risk factors, and our most recent form 10-K and subsequent form 10-Q filed with the Securities and Exchange Commission and available@www.sec.gov and on our website at www.novavax.com as well as subsequent filings with the SEC.